miR-204-5p 靶向的 AP1S2 对甲状腺乳头状癌是必需的。

MiR-204-5p-targeted AP1S2 is necessary for papillary thyroid carcinoma.

机构信息

Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, 130021, PR China; National Health Commission Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, 130021, PR China.

State Key Laboratory of Quality Research in Chinese Medicine and School of Pharmacy, Macau University of Science and Technology, 999078, PR China.

出版信息

Mol Cell Endocrinol. 2023 Aug 20;574:111993. doi: 10.1016/j.mce.2023.111993. Epub 2023 Jun 15.

DOI:10.1016/j.mce.2023.111993

PMID:37328093

Abstract

MiR-204-5p, as a tumour suppressor, has been found in several cancers. However, whether miR-204-5p is involved in papillary thyroid carcinoma (PTC) has not yet been investigated. In this study, we identified miR-204-5p as a down-regulated miRNA in PTC tissues, unveiling that the levels of miR-204-5p in serum of patients with PTC were linked to PTC risk, and that the expression in patients concomitant with both PTC and benign lesions was much lower than that in patients only with PTC. Furthermore, we documented that miR-204-5p inhibited proliferation, migration, invasion, and cell cycle progression and triggered apoptosis of PTC cells via cell biology experiments. Finally, we identified that AP1S2 was a target of miR-204-5p using RNA-seq, iTRAQ, and bioinformatics prediction. Overall, miR-204-5p functions as a suppressor for PTC pathogenesis via the miR-204-5p/AP1S2 axis.

摘要

miR-204-5p 作为一种肿瘤抑制因子，已在多种癌症中被发现。然而，miR-204-5p 是否参与甲状腺乳头状癌（PTC）尚未被研究。在这项研究中，我们鉴定出 miR-204-5p 在 PTC 组织中下调，揭示了 PTC 患者血清中 miR-204-5p 的水平与 PTC 风险相关，并且在同时患有 PTC 和良性病变的患者中表达水平远低于仅患有 PTC 的患者。此外，我们通过细胞生物学实验证明 miR-204-5p 通过抑制增殖、迁移、侵袭和细胞周期进程，触发 PTC 细胞凋亡。最后，我们通过 RNA-seq、iTRAQ 和生物信息学预测鉴定出 AP1S2 是 miR-204-5p 的靶标。总的来说，miR-204-5p 通过 miR-204-5p/AP1S2 轴发挥抑制 PTC 发病机制的作用。